Evaluation of the EUROIMMUN automated chemiluminescence immunoassays for measurement of four core biomarkers for Alzheimer's disease in cerebrospinal fluid.

ABSTRACT:

Introduction

Robust immunoassays for quantification of Alzheimer's disease (AD)-specific biomarkers are required for routine diagnostics. We report analytical performance characteristics of four new chemiluminescence immunoassays (ChLIA, EUROIMMUN) running on closed, fully automated random-access instruments for quantification of Aβ_1-40, Aβ_1-42, tTau, and pTau(181) in human cerebrospinal fluid (CSF).

Methods

ChLIAs were validated according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). Optimal cut-offs for biomarkers and biomarker ratios were determined using samples from 219 AD patients and 220 patients with AD-related symptoms. For performance comparison, biomarker concentrations were measured in 110 diagnostic leftover s

SUBMITTER: Rompler K 

PROVIDER: S-EPMC11417521 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature